Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Beta-lactam antibiotic Clear all
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01984684
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
delafloxacin, vancomycin, aztreonam
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.

NCT02809131
View directory record Official record
Conditions
Sick Sinus Syndrome, Complete Heart Block, Syncope, Chronic Systolic Heart Failure
Interventions
polymixin/bacitracin, cephalexin, or levofloxacin, or clindamycin, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?

NCT02554383
View directory record Official record
Conditions
Sinusitis, Respiratory Tract Infections
Interventions
Amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Years to 11 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Bardstown, Kentucky • Gresham, Oregon • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 2, 2026, 5:20 AM EDT
Recruiting Phase 4 Interventional

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

NCT05548283
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Beta-lactam antibiotic, Aminoglycoside
Drug
Lead sponsor
Chris Goss
Other
Eligibility
6 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

NCT00307099
View directory record Official record
Conditions
Bacterial Infection
Interventions
Meropenem, Standard antibiotic therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 2, 2026, 5:20 AM EDT
Enrolling by invitation Phase 4 Interventional

Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement

NCT07549542
View directory record Official record
Conditions
Antibiotic Prophylaxis Surgery
Interventions
CeFAZolin 1000 MG, Saline (0.9%, sterile, for infusion)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 2, 2026, 5:20 AM EDT
Recruiting Phase 4 Interventional

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

NCT05447559
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Cefazolin, Water for injection
Drug
Lead sponsor
Monash University
Other
Eligibility
18 Years and older
Enrollment
9,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

NCT06709521
View directory record Official record
Conditions
Bacterial Infection
Interventions
Iohexol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

NCT01825408
View directory record Official record
Conditions
Sinusitis
Interventions
Doxycycline, Azithromycin, Augmentin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 1 Interventional

The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures

NCT04198129
View directory record Official record
Conditions
Jaw Fractures, Infection
Interventions
Antibiotic treatment (Unasyn or Cleocin), Antibiotic treatment (Augmentin or Cleocin), Control Group
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional Results available

Antibiotic Duration in Post-appendectomy Abscess

NCT03795194
View directory record Official record
Conditions
Complicated Appendicitis, Perforated Appendicitis
Interventions
ampicillin/clavulanate
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 2, 2026, 5:20 AM EDT
Not listed Phase 4 Interventional

Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis

NCT05867654
View directory record Official record
Conditions
Osteomyelitis of Jaw
Interventions
Amoxicillin-clavulanate 875mg/125mg q12hrs, oral clindamycin 300mg q6hrs, Levofloxacin 750mg QID
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)

NCT02707042
View directory record Official record
Conditions
Normal Physiology, Healthy
Interventions
Amoxicillin, Azithromycin, Control
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

NCT02166476
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis
Interventions
Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

NCT00002682
View directory record Official record
Conditions
Lymphoma
Interventions
Amoxicillin, Bismuth Subsalicylate, Clarithromycin, Metronidazole Hydrochloride, Omeprazole, Tetracycline Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 2, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional Results available

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

NCT02015637
View directory record Official record
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 2, 2026, 5:20 AM EDT
Not listed Not applicable Interventional

Does a Safety Difference Exist Between IV Push and IV Piggyback Antibiotics?

NCT03360617
View directory record Official record
Conditions
Infection
Interventions
Syringe IV Push over 2-3 minutes, Piggyback over 30 minutes
Device
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 2, 2026, 5:20 AM EDT